Calculating The Intrinsic Value Of IDEXX Laboratories, Inc. (NASDAQ:IDXX)
How far off is IDEXX Laboratories, Inc. ( NASDAQ:IDXX ) from its intrinsic value? Using the most recent financial data...
Simply Wall St. · 3d ago
Goldman Sachs Adjusts IDEXX Laboratories' Price Target to $530 From $615, Maintains Neutral Rating
MT Newswires · 4d ago
IDEXX Laboratories to Present at Stifel Conference and Announces 2022 Investor Day
IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, will participate in the Stifel Jaws & Paws Conference on Wednesday, June 1, 2022. Jay Mazelsky, President and C...
PR Newswire · 4d ago
Baron Funds: “We Expect IDEXX’s Margins to Continue to Improve”
Baron Funds, an asset management firm, published its “Baron Asset Fund” first quarter 2022 investor letter – a copy of which can be downloaded here. Baron Asset Fund (the “Fund”) fell 14.52% (Institutional Shares), while the Russell Midcap Growth Index (th...
Insider Monkey · 4d ago
IDEXX Laboratories Earnings Perspective: Return On Capital Employed
According to Benzinga Pro, during Q1, IDEXX Laboratories (NASDAQ:IDXX) earned $193.97 million, a 19.16% increase from the preceding quarter. IDEXX Laboratories also posted a total of $836.55 million in sales, a 4.43% increase since Q4.
Benzinga · 5d ago
11 Companies in Focus After Releasing Their Earnings Reports
In this article, we will take a look at the 11 companies in focus after releasing their earnings reports. You can skip our detailed analysis of these companies and go directly to the 5 Companies in Focus After Releasing Their Earnings Reports. Notable cons...
Insider Monkey · 05/05 19:04
IDEXX Laboratories stock slips on mixed Q1 earnings, cut in FY revenue and EPS guidance
IDEXX Laboratories (NASDAQ:IDXX) stock has lost 6.5% to $384.78 in Thursday afternoon trade, after the veterinary services company reported a mixed set of Q1 2022 earnings and cut its FY
Seekingalpha · 05/05 17:38
IDEXX downgraded at BofA citing “soft 2022 start”
IDEXX Laboratories (NASDAQ:IDXX) has extended the post-earnings losses to the second straight session on Thursday after Bank of America lowered its rating on the animal health company to Neutral from
Seekingalpha · 05/05 17:06
--JPMorgan Adjusts Price Target for IDEXX Laboratories to $625 From $725, Maintains Overweight Rating
MT Newswires · 05/05 12:51
--Morgan Stanley Adjusts IDEXX Laboratories' Price Target to $603 from $732, Keeps Overweight Rating
MT Newswires · 05/05 12:45
--BofA Securities Downgrades IDEXX Laboratories to Neutral From Buy, Adjusts Price Target to $470 From $550
MT Newswires · 05/05 06:35
Markets Stage Big Rally Following Historic 50 Basis Point Rate Hike
U.S. indices rallied sharply into Wednesday's close after the Federal Reserve announced it would raise the key interest rate by 50 basis points.
Benzinga · 05/04 20:15
Is Now An Opportune Moment To Examine IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
IDEXX Laboratories, Inc. ( NASDAQ:IDXX ) received a lot of attention from a substantial price movement on the NASDAQGS...
Simply Wall St. · 05/04 15:24
IDEXX (IDXX) Q1 Earnings Surpass Estimates, Margins Down
Strong sales at the CAG and Water businesses drove IDEXX's (IDXX) first-quarter 2022 revenues.
Zacks · 05/04 14:48
IDEXX stock falls on Q1 profit miss, 2022 forecast below estimates
IDEXX Laboratories (NASDAQ:IDXX -10.6%) stock falls after the company posted lower-than-expected Q1 profit and revised its 2022 revenue forecast, that were below wall street estimates.  The company now expects 2022
Seekingalpha · 05/04 13:41
Idexx Laboratories (IDXX) Q1 Earnings Beat Estimates
Idexx (IDXX) delivered earnings and revenue surprises of 0.89% and 0.57%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/04 11:55
IDEXX Laboratories Q1 EPS $2.27 Beats $2.26 Estimate, Sales $837.00M Miss $839.72M Estimate
IDEXX Laboratories (NASDAQ:IDXX) reported quarterly earnings of $2.27 per share which beat the analyst consensus estimate of $2.26 by 0.44 percent. This is a 3.4 percent decrease over earnings of $2.35 per share from the
Benzinga · 05/04 10:41
BRIEF-Idexx Laboratories Announces First Quarter Results · 05/04 10:36
IDEXX Laboratories Non-GAAP EPS of $2.24 misses by $0.01, revenue of $836.54M in-line
IDEXX Laboratories press release (NASDAQ:IDXX): Q1 Non-GAAP EPS of $2.24 misses by $0.01. Revenue of $836.54M (+7.6% Y/Y) in-line. Re-calibrated 2022 revenue outlook of $3.39B-$3.46B vs consensus of $3.54B reflects
Seekingalpha · 05/04 10:35
IDEXX Laboratories Q1 Earnings Slide, Revenue Rises; Company Lowers 2022 Outlook
MT Newswires · 05/04 07:27
Webull provides a variety of real-time IDXX stock news. You can receive the latest news about Idexx Labs Inc through multiple platforms. This information may help you make smarter investment decisions.
About IDXX
IDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. It also sells a line of portable electrolytes and blood gas analyzers used in the human diagnostics market. Its segments include Companion Animal Group (CAG), Water quality products (Water), and Livestock, Poultry and Dairy (LPD). The CAG segment CAG develops, designs, manufactures, and distributes products and performs services for veterinarians and the biomedical analytics market, primarily related to diagnostics and information management. The Water segment develops, designs, manufactures, and distributes a range of products used in the detection of various microbiological parameters in water. The LPD segment develops, designs, manufactures, and distributes diagnostic tests and related instrumentation and performs services that are used to manage the health status of livestock and poultry.